Extract

This single-arm open-label study assessed the safety, feasibility, and efficacy of trastuzumab emtansine (T-DM1) after the completion of anthracycline-based adjuvant/neoadjuvant chemotherapy in patients with early HER2-positive breast cancer. Patients received T-DM1 3.6 mg/kg intravenously on Day 1 of each 3-week cycle, for up to 17 cycles.

Inclusion criteria

• Breast Cancer

Country

• Belgium
• France
• Germany
• Italy
• Korea, Republic of
• Russian Federation
• Spain
• United States

Links

• ictrp
• nct